Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years, whether currently in hospital or attending as an outpatient
- People who have been diagnosed with major depressive disorder (MDD) — either a single episode or recurring episodes — according to standard diagnostic guidelines (DSM-5)
- People whose depression symptoms score at least 17 points on a standard 17-item depression rating scale (HAMD-17) at the start of the screening period
- People who have not taken any medication for their current episode of depression at the start of the screening period
- People who are planned to be treated with a single antidepressant called Escitalopram at the start of the screening period
- People whose depression score on the HAMD-17 improved by less than 20% after two weeks of taking the highest tolerated dose of Escitalopram
- People who have completed more than a primary school level of education and are able to understand the study questionnaires
- People who have signed a consent form agreeing to take part in the trial
Who may not be able to join:
- People who have ever been diagnosed with bipolar disorder, a neurodevelopmental disorder, a neurocognitive disorder, a schizophrenia-related condition, or a substance use or addiction disorder
- People who are currently experiencing significant symptoms such as delusions or hallucinations
- People who currently have a serious or unstable condition affecting the brain, heart, lungs, liver, kidneys, hormones, blood, or other body systems, where the research team considers participation unsuitable
- People who are currently considered at serious risk of suicide, reflected by a score of 3 or more on the suicide-related item of the HAMD-17 rating scale
- People who have an inflammation-related disease
- People who have a gastrointestinal condition such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, celiac disease, digestive system tumours, or other structural digestive system problems
- People who have previously had surgery on the gastrointestinal (digestive) system
- People who have used antibiotics, probiotics, prebiotics, or traditional Chinese medicine products continuously for more than 2 weeks in the 3 months before joining the study
- People who are allergic to any ingredients in capsules or their contents
- People who are pregnant or breastfeeding
- People who are unable or unwilling to swallow capsules (for example, due to difficulty swallowing)
- People who have received a type of brain stimulation treatment called MECT (modified electroconvulsive therapy) in the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86 + 010-86430066
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The differences in efficacy(HAMD-17 score reduction rate ≥50%) between the two groups
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.